Header

UZH-Logo

Maintenance Infos

Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning


Jäger, Dirk; Taverna, Christian; Zippelius, Alfred; Knuth, Alexander (2004). Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunology, Immunotherapy, 53(3):144-147.

Abstract

The presence of tumor infiltrating T cells has been shown to be associated with a favorable prognosis in different tumor types. Several strategies have been developed to identify relevant tumor antigens which can be used for active immunotherapy strategies. The SEREX technique (serological analysis of cDNA expression libraries) identifies tumor antigens based on a spontaneous humoral immune response in cancer patients. This technique is not limited to tumor types that can be grown in cell culture or depends on established T cell clones recognizing the autologous tumor. Several steps of analysis are mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy: expression analysis; serological analysis with sera from tumor patients and normal individuals; identification of potential peptide epitopes for CD8 T cells and evaluation in T cell assays. This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1

Abstract

The presence of tumor infiltrating T cells has been shown to be associated with a favorable prognosis in different tumor types. Several strategies have been developed to identify relevant tumor antigens which can be used for active immunotherapy strategies. The SEREX technique (serological analysis of cDNA expression libraries) identifies tumor antigens based on a spontaneous humoral immune response in cancer patients. This technique is not limited to tumor types that can be grown in cell culture or depends on established T cell clones recognizing the autologous tumor. Several steps of analysis are mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy: expression analysis; serological analysis with sera from tumor patients and normal individuals; identification of potential peptide epitopes for CD8 T cells and evaluation in T cell assays. This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1

Statistics

Citations

Dimensions.ai Metrics
47 citations in Web of Science®
46 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

34 downloads since deposited on 19 Oct 2018
19 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Immunology and Allergy
Life Sciences > Immunology
Health Sciences > Oncology
Life Sciences > Cancer Research
Language:English
Date:1 March 2004
Deposited On:19 Oct 2018 11:48
Last Modified:15 Apr 2021 14:53
Publisher:Springer
ISSN:0340-7004
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1007/s00262-003-0470-z

Download

Green Open Access

Download PDF  'Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 181kB
View at publisher